tiprankstipranks
Blurbs

JMP Securities Thinks Morphosys Ag’s Stock is Going to Recover

JMP Securities analyst Jason Butler reiterated a Buy rating on Morphosys Ag (MORResearch Report) today and set a price target of $32.00. The company’s shares closed last Tuesday at $5.54, close to its 52-week low of $4.35.

According to TipRanks.com, Butler ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.4% and a 39.6% success rate. Butler covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, ACADIA Pharmaceuticals, and Aquestive Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Morphosys Ag with a $17.00 average price target.

See today’s best-performing stocks on TipRanks >>

Based on Morphosys Ag’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $41.5 million and GAAP net loss of $123 million. In comparison, last year the company earned revenue of $47.19 million and had a GAAP net loss of $41.61 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.

Read More on MOR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More